Novo Nordisk rebrands to 'Novo,' CEO tells CNBC drugmaker needs to 'rethink' strategy amid obesity race
The Danish drugmaker called the changes the beginning of a new chapter for the company, which faces stiff competition from Eli Lilly.
Brief by WorldPing · Original reporting by CNBC World
WorldPing



